Clinical Trial Update: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for A6 in treating persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Brenner Tumor
• Ovarian Carcinoma
• Ovarian Clear Cell Cystadenocarcinoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian Epithelial Cancer
• Ovarian Mucinous Cystadenocarcinoma
• Ovarian Serous Cystadenocarcinoma
• Peritoneal Carcinoma
• Undifferentiated Ovarian Carcinoma

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 2 | Status: COMPLETED | Results posted: 2014-07-17